Edition:
United Kingdom

Erytech Pharma SA (ERYP.OQ)

ERYP.OQ on NASDAQ Stock Exchange Global Select Market

18.58USD
8:23pm GMT
Change (% chg)

$0.29 (+1.59%)
Prev Close
$18.29
Open
$18.98
Day's High
$19.08
Day's Low
$18.58
Volume
4,829
Avg. Vol
--
52-wk High
$30.48
52-wk Low
$18.28

Chart for

About

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​

* ‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​

10 Nov 2017

BRIEF-Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​

* ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS

10 Nov 2017

BRIEF-Erytech Pharma 9M net loss widens to 20.8 million euros

* ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO

07 Nov 2017

BRIEF-Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs

* Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍​ - sec filing

06 Nov 2017

BRIEF-Erytech Pharma ‍announces resubmission of european marketing authorization application for GRASPA

* ‍ANNOUNCES RESUBMISSION OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA IN ACUTE LYMPHOBLASTIC LEUKEMIA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Oct 2017

BRIEF-Erytech Pharma files for U.S. IPO of up to $100 mln of ADSS

* Erytech Pharma Sa files for U.S. IPO of up to $100 million of ADSS - SEC filing‍​

06 Oct 2017

BRIEF-Erytech Pharma H1 net loss widens to ‍​14.0 million euros

* ERYTECH REPORTS FIRST HALF 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

11 Sep 2017

BRIEF-Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival ‍​

* COMPLETE DATA DEMONSTRATE A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL ‍​

08 Sep 2017

BRIEF-Erytech announces collaboration with Queen’s University

* ERYTECH ANNOUNCES COLLABORATION WITH QUEEN’S UNIVERSITY TO ADVANCE ITS PRODUCT CANDIDATE FOR RARE METABOLIC DISORDERS

12 Jul 2017

Earnings vs. Estimates